ClinicalTrials.gg
RecruitingNCT06245304Updated Feb 7, 2024

Physiologic Pacing for Symptomatic First-Degree Heart Block

An interventional study of Dual chamber Medtronic pacemaker implantation. and DDD-50 pacing program in Symptomatic First-degree Heart Block, sponsored by Ascension Health. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-07.

Sponsored by Ascension Health · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Registered 3 months after the study started (first participant enrolled Oct 2023, registered Jan 2024).
  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 13 studies in Heart Block with a site in United States — 5 open to participants now, 5 under way, none of them phase 3. Heart Block · United States.

Started
2023
with 2 others
No phase
5 of 13
2 open now
Registered
11th of 13
by date
Lead sponsor
1 of 13
Ascension Health

Among the 13 studies in Heart Block with a site in United States, this one is one of 3 that started in 2023, is one of 5 with no phase, and was the 11th registered.

Heart Block

39 studies on the registry are indexed under Heart Block; 12 are open to participants now.

Browse Heart Block studies →

Open to participants now

5 of the 13 studies in Heart Block with a site in United States are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 10 Heart Block studies recruiting now, 7 (70%) set no upper age limit and 1 (10%) stops at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Heart Block with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine if physiologic pacing will improve symptoms and outcomes in patients with symptomatic first-degree heart block (pr interval ≥250ms).

Read the detailed description

The purpose of this study is to determine if physiologic pacing will improve symptoms and outcomes in patients with symptomatic first-degree heart block (pr interval ≥250ms). Patient will undergo a comparative effectiveness study where patients with symptomatic first-degree heart block (pr interval ≥250ms) undergo left bundle pacing (3830 lead) and are randomized to DDD-50 vs Managed Ventricular pacing-50 (MVP-50; AAI-DDD 50) and undergo a crossover at 3 months. This study will compare two standard of care options utilizing Food and Drug Administration (FDA) approved devices. Patients are evaluated at baseline, 3 months, and 6 months in terms of patient symptoms, exercise capacity, arrhythmia burden, and patient activity.

03

Conditions studied

  • Symptomatic First-degree Heart Block

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 18 or above
  • Ventricular (EF) > 50%
  • (NYHA) class II-IV
  • PR interval ≥250ms
  • Narrow QRS duration (≤140ms) or prolonged QRS duration with typical Right Bundle Branch Block (RBBB) morphology on 12 lead and sinus rhythm

Exclusion criteria

Exclusion Criteria:

  • Permanent atrial fibrillation (AF)
  • Patients who are unable to perform a 6 minute hall walk
  • Other serious medical condition with of less than 1 year
  • Lack of capacity to consent
  • Pregnancy
  • to use of the relevant study device or leads (as per current manuals from manufacturer)
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Other
    DDD-50 followed by AAI-DDD 50

    Patients will be programmed to DDD-50 first. After 3 months, patients will be programmed to AAI-DDD 50.

    Device: Dual chamber Medtronic pacemaker implantation. · Other: DDD-50 pacing program · Other: AAI-DDD 50 pacing program

  • Other
    AAI-DDD 50 followed by DDD-50

    Patients will be programmed to AAI-DDD-50 first. After 3 months, patients will be programmed to DDD 50.

    Device: Dual chamber Medtronic pacemaker implantation. · Other: DDD-50 pacing program · Other: AAI-DDD 50 pacing program

Interventions

  • DeviceDual chamber Medtronic pacemaker implantation.

    All patients will undergo a dual chamber Medtronic pacemaker implantation meeting approved indications for pacemaker implantation per Centers for Medicare \& Medicaid Services (CMS) guidelines. Pacemaker Model: Azure XT W1DR01. Right ventricular lead model: Medtronic 3830.

  • OtherDDD-50 pacing program

    This device programming attempts to increase the amount of ventricular pacing via the Medtronic 3830 lead. Since the enrolled patients have a prolonged PR interval, this programming attempts to synchronic atrial and ventricular contractions.

  • OtherAAI-DDD 50 pacing program

    This device programming attempts to encourage native conduction and minimize ventricular pacing via the Medtronic 3830 lead. This programming attempts to minimize ventricular pacing, which has been associated with worse outcomes by causing ventricular dyssynchrony between the left and right ventricles.

06

What researchers measure

Primary outcomes

  1. Quality of Life per the Minnesota Living with Heart Failure Questionnaire (MLHFQ)

    Determine if pacemaker programming influences quality of life based on Minnesota Living with Heart Failure Questionnaire (MLHFQ)

    Time frame: 6 months after pacemaker implantation.

Secondary outcomes

  1. Exercise capacity

    Determine if pacemaker programming influences exercise capacity (6 minute hall walk, Bruce protocol, or modified Bruce protocol).

    Time frame: 6 months after pacemaker implantation.

  2. Atrial fibrillation burden

    Determine if pacemaker programming influences overall burden of atrial fibrillation.

    Time frame: 6 months after pacemaker implantation.

  3. Patient activity

    Determine if pacemaker programming influences patient activity (as measured by device accelerometer).

    Time frame: 6 months after pacemaker implantation.

07

Study locations

1 of 1 sites recruiting
  • Ascension Saint Thomas Midtown
    Nashville, Tennessee 37203, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2023 (actual). Primary completion is estimated for Dec 2024, 14 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2024
First posted
Feb 7, 2024
StartActual
Oct 1, 2023
Primary completionEst.
Dec 31, 2024
CompletionEst.
Jun 30, 2025
Last update
Feb 7, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 7, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06245304
Lead sponsor
Ascension Health
Collaborators
Medtronic
Responsible party
Daniel Kaiser (Principal Investigator, Ascension Health) — Principal investigator
First posted
Feb 7, 2024
Start date
Oct 1, 2023
Primary completion
Dec 31, 2024 (estimated)
Completion
Jun 30, 2025 (estimated)
Last update
Feb 7, 2024

Study contacts

Daniel Kaiser, MD
Contact
daniel.kaiser@ascension.org
6153295144
Tonya Fambrough, RN
Contact
tonya.fambrough@ascension.org
6152223085

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion